These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 12723745)
1. Risk factors associated with the development of gastroduodenal ulcers due to the use of NSAIDs. Wolfe MM Int J Clin Pract Suppl; 2003 Apr; (135):32-7. PubMed ID: 12723745 [TBL] [Abstract][Full Text] [Related]
3. [Prevention and treatment of non-steroidal anti-inflammatory drug gastroenteropathy]. Lanas A Rev Gastroenterol Mex; 2004; 69(4):251-60. PubMed ID: 15765979 [TBL] [Abstract][Full Text] [Related]
4. [Prophylaxis and therapy of gastropathy caused by non-steroidal anti-inflammatory drugs]. László A Orv Hetil; 2002 Jul; 143(27):1643-8. PubMed ID: 12180001 [TBL] [Abstract][Full Text] [Related]
5. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications--review and recommendations based on risk assessment. Chan FK; Graham DY Aliment Pharmacol Ther; 2004 May; 19(10):1051-61. PubMed ID: 15142194 [TBL] [Abstract][Full Text] [Related]
6. Prevention and treatment of gastrointestinal symptoms and complications due to NSAIDs. McCarthy DM Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):755-73. PubMed ID: 11566039 [TBL] [Abstract][Full Text] [Related]
8. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912 [TBL] [Abstract][Full Text] [Related]
9. Ulcers, Helicobacter pylori infection, platelets and gastrointestinal complications of non-steroidal anti-inflammatory drugs: what are the connections? McCarthy DM Eur J Surg Suppl; 2002; (587):89-99. PubMed ID: 16144207 [TBL] [Abstract][Full Text] [Related]
10. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. Pilotto A; Franceschi M; Leandro G; Paris F; Cascavilla L; Longo MG; Niro V; Andriulli A; Scarcelli C; Di Mario F Aliment Pharmacol Ther; 2004 Nov; 20(10):1091-7. PubMed ID: 15569111 [TBL] [Abstract][Full Text] [Related]
12. [Secondary and primary prophylaxis of gastropathy associated with nonsteroidal antiinflammatory drugs or low-dose-aspirin: a review based on four clinical scenarios]. Limmer S; Ittel TH; Wietholtz H Z Gastroenterol; 2003 Aug; 41(8):719-28. PubMed ID: 12910426 [TBL] [Abstract][Full Text] [Related]
13. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs. Ray WA; Chung CP; Stein CM; Smalley WE; Hall K; Arbogast PG; Griffin MR Gastroenterology; 2007 Sep; 133(3):790-8. PubMed ID: 17854591 [TBL] [Abstract][Full Text] [Related]
14. Role of acid suppressants in prophylaxis of NSAID damage. Chan FK; Sung JJ Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):433-45. PubMed ID: 11403537 [TBL] [Abstract][Full Text] [Related]
15. Gastro-duodenal protection in an era of cyclo-oxygenase-2-selective nonsteroidal anti-inflammatory drugs. Naesdal J; Wilson I Eur J Gastroenterol Hepatol; 2001 Dec; 13(12):1401-6. PubMed ID: 11742186 [TBL] [Abstract][Full Text] [Related]
16. NSAID-induced gastrointestinal damage. A critical review of prophylaxis and therapy. McCarthy DM J Clin Gastroenterol; 1990; 12 Suppl 2():S13-20. PubMed ID: 1978842 [TBL] [Abstract][Full Text] [Related]
17. [Treatment and prevention of gastrointestinal complications caused by non-steroidal antiphlogistic agents]. Rybár I; Kriska M; Vavrecka A; Hyrdel R; Rovenský J Cas Lek Cesk; 1999 Nov; 138(22):675-80. PubMed ID: 10746025 [TBL] [Abstract][Full Text] [Related]
18. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications. Goldstein JL; Howard KB; Walton SM; McLaughlin TP; Kruzikas DT Clin Gastroenterol Hepatol; 2006 Nov; 4(11):1337-45. PubMed ID: 17088110 [TBL] [Abstract][Full Text] [Related]
19. Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level. Varas-Lorenzo C; Maguire A; Castellsague J; Perez-Gutthann S Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):366-76. PubMed ID: 16897817 [TBL] [Abstract][Full Text] [Related]
20. Utilization of non-steroidal anti-inflammatory drugs in Quebec: adherence to the Canadian consensus on prescription guidelines. Moride Y; Ducruet T; Boivin JF; Lavoie F; Rochon S Can J Clin Pharmacol; 2005; 12(2):e201-11. PubMed ID: 15998959 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]